1Porter KE,Naik J,Turner NA,et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration[J]. J Vasc Surg, 2002,36(1 ) : 150-157.
2Stefanadis C, Toutouzas K, Vavuranakis M, et al. Statin treatment is associated with reduced thermal heterogeneity in human atheroselerotic plaques[J]. Eur Heart J, 2002, 23 (21): 1664-1669.
3Puccetti L, Bruni F, Bova G, et al. Effect of diet and treatment withstatins on platelet-dependent thrombin generation in hypercholester-olemic subjects[J]. Nutr Metab Cardiovasc Dis, 2001,11 (6) :378-387.
4Ramana KV,Chandra D,Srivastava S,et al. Aldose reductase mediates the mitogenic signals of cytokines[J]. Chem Biol Interact, 2003,143:587-596.
5Bae JH,Bassenge E, KimKY,et al. Effects of low-dose atorvas tatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting[J]. J Cardiovasc Phannaco Ther,2004,9(3):185-192.
7Serruy PW, Foley DP, Jackson G, et al. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplastyl final results of fluvastatin angiographic restenosis (FLARE) trial[J]. Eur Heart J, 1999,20(1) :58-69.
8Grundy SM,Cleeman JI,Bairey Merz CN,et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education ProgramAdult Treatment Panel Ⅲ guidelines[J]. Circulation,2004,110(2) :227-239.
9de Lemos JA,Blazing MA,Wiviott SD,et al. Early intensive vs a delayed conservative simvvastatin strategy in patients with acute coronary syndromes[J]. JAMA, 2004,292(11): 1307-1316.
10LaRosa JC,Grundy SM,Waters DD,et al. Treating to NeW Targets (TNT)Investigators. Intensive Lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005,352(14) : 1425-1435.
二级参考文献7
1Reimer S,Moussa I,Akiyama T,etal.Long-term clinical followup after successful repeat percutaneous intervention for stent restenosis.J Am Coll Cardiol,1997,30:186-192.
2Famier M.Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative.Am J Cardiovasc Drugs,2003,3:169-178.
3Martin G,Duez H,Blanquart C,et al.Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I.J Cin Invest,2001,107:1423-1432.
4Andersen H,Maeng M,Thorwest M,et al.Constrictive vascular remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury.Insights from a new porcine coronary restenosis model.Circulation,1995,92:1649.
5Dussaillant GR,Mintz GS,Pilchard AD,et al.Small stent size and intimal hyperplasia contribute to restenosis:A volumetric intravascular ultrasound analysis.J Am Coll Cardiol,1995,26:720-724.
6Takebayashi H,Mintz CS,Carlier SG,et al.Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation.Circulation,2004,110:3430-3434.
